Primary Biliary Cholangitis Therapeutics Market Analysis: $1.64 Billion by 2029 With a CAGR of 12.9%

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

Primary Biliary Cholangitis Therapeutics Market Value Projection: How Much Will the Market Size by 2025?
Over the past few years, the market size of primary biliary cholangitis therapeutics has seen significant expansion. It is anticipated that the market value will surge from $0.89 billion in 2024 to $1.01 billion in 2025, experiencing a compound annual growth rate (CAGR) of 13.3%. Factors such as increased awareness of autoimmune liver diseases, mounting clinical proof favoring growth in liver function examination, escalated funding in hepatology research, and a higher incidence rate of autoimmune diseases have contributed to this growth in the historical period.

What Will Be the Market Growth Forecat for Primary Biliary Cholangitis Therapeutics in 2029?
The market size for therapeutics in primary biliary cholangitis is projected to grow significantly in the coming years. It is estimated to reach a value of $1.64 billion in 2029, growing at a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this growth in the forecast period include increased acceptance of second-line therapies, the expansion of a promising therapeutic pipeline, a rise in combined therapies, amplified global availability of diagnostic and specialty care, along with increased efforts in patient advocacy and education. The forecast period will also witness key trends such as personalized treatment strategies, widespread adoption of second-line treatments, a focus on non-invasive biomarkers, an increased stress on symptom management, and the incorporation of real-world evidence (RWE).

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-therapeutics-global-market-report

What Are the Core Competitive Drivers in the Primary Biliary Cholangitis Therapeutics Industry?
The growing incidence of liver diseases is anticipated to stimulate the expansion of the primary biliary cholangitis therapeutics market. Liver diseases signify a collection of conditions that hinder the liver's standard function, often causing inflammation, scarring, or liver failure. The growing incidence is due to an increase in alcohol intake, as excessive alcohol can damage liver cells, leading to inflammation and persistent liver conditions. Primary biliary cholangitis therapeutics assist in managing liver diseases by focusing on bile duct inflammation, slowing the progression of the disease, and maintaining liver function. They improve patient results by lessening symptoms, improving quality of life, and postponing the need for liver transplantation. For instance, as per the Centers for Disease Control and Prevention in March 2022, a US governmental agency, fatalities from chronic liver diseases in Texas ascended to 5,079, up from 4,930 in 2021. Hence, the growing prevalence of liver diseases is fueling the expansion of the primary biliary cholangitis therapeutics market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp

Which Primary Biliary Cholangitis Therapeutics Market Segment Is Projected to See the Fastest Growth?
The primary biliary cholangitis therapeutics market covered in this report is segmented -

1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action
3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
4) By Use: Human, Veterinary

Subsegments:
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid
2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid
3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates

Which Trends Are Opening New Opportunities in the Primary Biliary Cholangitis Therapeutics Market?
Companies that hold a significant portion of the primary biliary cholangitis therapeutic market are primarily focused on creating innovative products and achieving necessary approvals. One such example is the development of peroxisome proliferator-activated receptor agonists, which aid in enhancing bile acid metabolism and delay the disease's advancement. These peroxisome proliferator-activated receptor (PPAR) agonists are types of medications that trigger the PPAR proteins that govern the genes linked to metabolism, inflammation, and energy balance. For example, Gilead Sciences Inc., a pharmaceutical organization based in the United States, in August 2024, received expedited approval from the U.S. Food and Drug Administration (FDA) for their drug Livdelzi (seladelpar). This drug, intended to treat adults with primary biliary cholangitis (PBC) who have shown inadequate response to ursodeoxycholic acid (UDCA) or who display intolerance to UDCA, is an orally administered, selective PPARd agonist. It functions by triggering the PPARd receptor to control genes that aid in reducing liver inflammation, enhance bile acid metabolism and slow the progression of primary biliary cholangitis (PBC).

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25887&type=smp

Who Are the Leaders in the Primary Biliary Cholangitis Therapeutics Market?
Major companies operating in the primary biliary cholangitis therapeutics market are F. Hoffmann-La Roche Ltd, Parvus Therapeutics, Novartis AG, Gilead Sciences Inc., Viatris Inc., Ipsen Pharma, Hanmi Pharmaceutical Co. Ltd., Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., Durect Corporation, COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics

Which Regional Primary Biliary Cholangitis Therapeutics Markets Offer the Greatest Growth Potential?
North America was the largest region in the primary biliary cholangitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.